N-803 and BCG

DRUG2 trials

Sponsors

ImmunityBio, Inc.

Conditions

Bladder CancerNon-muscle Invasive Bladder Cancer (NMIBC)

Phase 2

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

Active, not recruitingNCT03022825

ImmunityBio, Inc.Bladder Cancer

Start: 2017-06-02End: 2029-03-01Updated: 2025-10-16

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

Not yet recruitingNCT06829823

ImmunityBio, Inc.Non-muscle Invasive Bladder Cancer (NMIBC)

Start: 2025-11-30End: 2029-11-30Target: 20Updated: 2025-10-16

Related Papers

A matched-adjusted indirect comparison (MAIC) of nogapendekin alfa inbakicept-pmln plus bacillus Calmette–Guérin (NAI+BCG) and pembrolizumab in patients with BCG-unresponsive non–muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) ± papillary disease.

Journal of Clinical Oncology2026-05-28

Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte–Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin–Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer

The Journal of Urology2025-09-161 citations

N-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review

Future Oncology2024-07-027 citations

MP16-03 N-803 PLUS BCG COMPLETE RESPONSE RATE IN NMIBC CIS SUBJECTS: BCG REFRACTORY, RELAPSED, CHECKPOINT FAILURE, AND CHEMOTHERAPY FAILURE; UPDATED RESULTS (QUILT 3.032)

The Journal of Urology2024-04-152 citations

Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin‒Unresponsive Nonmuscle-Invasive Bladder Cancer

Urology Practice2024-01-1613 citations

Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15RαFc superagonist N-803 plus BCG.

Journal of Clinical Oncology2023-02-203 citations

Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC).

Journal of Clinical Oncology2022-06-0151 citations

PLLBA-01 FINAL CLINICAL RESULTS OF PIVOTAL TRIAL OF IL-15RΑFC SUPERAGONIST N-803 WITH BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CIS AND PAPILLARY COHORTS

The Journal of Urology2022-04-075 citations

Positive efficacy and safety phase 3 results in both CIS and papillary cohorts BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) after IL-15RαFc superagonist N-803 (Anktiva) and BCG infusion.

Journal of Clinical Oncology2022-02-1610 citations

PD09-05 PHASE 2/3 CLINICAL RESULTS OF IL-15RΑFC SUPERAGONIST N-803 WITH BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CARCINOMA IN-SITU (CIS) PATIENTS.

The Journal of Urology2021-08-041 citations

Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients.

Journal of Clinical Oncology2021-02-2022 citations

Preliminary phase 2 clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients.

Journal of Clinical Oncology2019-05-2017 citations

LBA-18 PRELIMINARY PHASE 2 CLINICAL RESULTS OF IL-15RαFC SUPERAGONIST N-803 WITH BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) PATIENTS DEMONSTRATES 82% CR OF CARCINOMA IN SITU (CIS)

The Journal of Urology2019-04-012 citations

A multicenter clinical trial of intravesical BCG in combination with ALT-803 in patients with BCG-unresponsive non-muscle invasive bladder cancer.

Journal of Clinical Oncology2018-02-203 citations